CoChat

Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

Attal, Michel, Harousseau, Jean-Luc, Facon, Thierry, Guilhot, François, Doyen, Chantal, Fuzibet, Jean-Gabriel, Monconduit, Mathieu, Hulin, Cyrille, Caillot, Denis, Bouabdallah, Reda, Voillat, Laurent, Sotto, Jean-Jacques, Grosbois, Bernard, Bataille, Regis · 2003 · New England Journal of Medicine

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

BACKGROUND: We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. METHODS: At the time of diagnosis, 399 previously untreated patients under the age of 60 years were randomly assigned to receive a single or double transplant. RESULTS: A complete or a very good partial response was achieved by 42 percent of patients in the single-transplant group and 50 percent of patients in the double-transplant group (P=0.10). The probability of surviving event-free for seven years after the diagnosis was 10 percent in the single-transplant group and 20 percent in the double-transplant group (P=0.03). The estimated overall seven-year survival rate was 21 percent in the single-transplant group and 42 percent in the double-transplant group (P=0.01). Among patients who did not have a very good partial response within three months after one transplantation, the probability of surviving seven years was 11 percent in the single-transplant group and 43 percent in the double-transplant group (P<0.001). Four factors were significantly related to survival: base-line serum levels of beta2-microglobulin (P<0.01) and lactate dehydrogenase (P<0.01), age (P<0.05), and treatment group (P<0.01). CONCLUSIONS: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa032290

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 7

  1. Barlogie B, 1991, Bone Marrow Transplant, 7, 71
  2. Fermand J-P, 1999, Blood, 94, 396a
  3. Blade J, 2001, Blood, 98, 815a
  4. Palumbo A, 2001, Blood, 98, 849a
  5. Fermand J-P, 2001, Blood, 98, 815a
  6. Richardson P, 2002, Blood, 100, 104a
  7. Sirohi B, 2002, Bone Marrow Transplant, 29, S12

Cited by

See all 987

Metadata

Authors
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.-J., Grosbois, B., & Bataille, R.
Affiliations
  • Hôpital Purpan (FR)
  • Hôpital Claude Huriez (FR)
  • Centre Hospitalier Universitaire de Poitiers (FR)
  • Centre Hospitalier Universitaire de Nice (FR)
  • Centre Henri Becquerel (FR)
  • Centre Hospitalier Régional et Universitaire de Nancy (FR)
  • CHU Dijon Bourgogne (FR)
  • Centre Hospitalier Universitaire de Besançon (FR)
  • Hôpital Albert Michallon (FR)
Venue
New England Journal of Medicine
Published
2003-12-25
Volume
349
Issue
26
Pages
2495-2502
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1982499121
Cited by
984
References
16
Citations by year
2026: 3 · 2025: 13 · 2024: 18 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 33 · 2019: 18 · 2018: 35 · 2017: 28 · 2016: 24 · 2015: 37 · 2014: 38 · 2013: 53 · 2012: 42
FWCI
34.51
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Access to Libraries (submittedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords
multiple myeloma, autologous stem cell transplantation, high-dose chemotherapy, overall survival, event-free survival, very good partial response, beta2-microglobulin, lactate dehydrogenase, prognostic factors
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Prognosis, Transplantation, Autologous, Vincristine, Survival Rate, Multivariate Analysis, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.